





## **FINLAND**


Pharmaceuticals Pricing Board Jaana Martikainen

email: jaana.martikainen@gov.fi phone: +358 295 163 174

Social Insurance Institution of Finland (Kela) Kati Sarnola

kati.sarnola@kela.fi

+ 358 50 345 35 09



# Pharmaceutical pricing and reimbursement policies

# **Pricing** of medicines

#### **OUTPATIENT SECTOR**

Non-reimbursable pharmaceuticals can be priced freely.

Pharmaceuticals Pricing Board (subordinated to the Ministry of Social Affairs and Health) confirms reimbursement status and a wholesale price of reimbursable medicinal.

Pricing procedures includes:

- External price referencing 0
- Internal price referencing 0
- Health economic evaluations

For generics: price linkage, generic substitution and reference pricing (RPS) For biosimilars: price linkage, RPS (in stages from the beginning of 2024)

Decisions valid max 5 years; for new active substance max 3 years.

Wholesale remuneration: Not controlled

Pharmacy remuneration: Statutory regressive mark-up separately for prescription and non-pre-

scription pharmaceuticals

VAT: Standard rate 24%, reduced rate for medicines 10%.


#### INPATIENT SECTOR

Council for Choices in Health Care in Finland is to issue recommendations on services incl. medicines included in the public health services. The Council works in conjunction with the Ministry of Social Affairs and Health.

Health care regions acquire the medicines through tendering and price negotiations. Very expensive medicines are acquired nationally.

# Coverage/ Reimbursement

### **OUTPATIENT CARE**



RPS: Generic groups: same active substance, quantity and pharmaceutical form, closely corresponding package size

Mechanisms for vulnerable groups: Higher reimbursement rate for medicines used for chronic and severe diseases (Special reimbursements).

### **INPATIENT CARE**

Pharmaceuticals used in hospitals are included in the patient's daily charge.